Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts).

被引：0
|
作者：
Kazushi, Yoshida
Inoue, Akira
Sugawara, Shunichi
Murakami, Shuji
Saka, Hideo
Morita, Satoshi
Kim, Young Hak
Imamura, Fumio
Takeda, Koji
Nakagawa, Kazuhiko
Takeda, Masayuki
Atagi, Shinji
Hasegawa, Yoshikazu
Yamamoto, Nobuyuki
Katakami, Nobuyuki
Yoshioka, Hiroshige
Iwamoto, Yasuo
Okamoto, Isamu
Seto, Takashi
Ohe, Yuichiro
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[3] Sendai Kousei Hosp, Sendai, Miyagi, Japan
[4] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[5] Nagoya Med Ctr, Nagoya, Aichi, Japan
[6] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[7] Kyoto Univ Hosp, Kyoto, Japan
[8] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Pulm Oncol, Osaka, Japan
[9] Osaka City Gen Hosp, Dept Med Oncol, Osaka, Japan
[10] Kinki Univ, Sch Med, Osaka, Japan
[11] Kinki Univ, Fac Med, Dept Med Oncol, Osaka, Japan
[12] Kinki Chuo Chest Med Ctr, Osaka, Japan
[13] Kinki Univ, Sakai Hosp, Sch Med, Sakai, Osaka, Japan
[14] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
[15] Inst Biomed Res & Innovat, Div Integrated Oncol, Kobe, Hyogo, Japan
[16] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan
[17] Hiroshima City Hosp, Dept Med Oncol, Hiroshima, Japan
[18] Kyushu Univ Hosp, Fukuoka, Japan
[19] Natl Kyushu Canc Ctr, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e20503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20503
引用
收藏
页数：3
相关论文
共 50 条
  • [41] European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review
    Shah, Riyaz
    Girard, Nicolas
    Nagar, Saurabh P.
    Griesinger, Frank
    Roeper, Julia
    Davis, Keith L.
    Karimi, Parisa
    Sawyer, William
    Yu, Ning
    Taylor, Aliki
    Feliciano, Josephine
    DRUGS-REAL WORLD OUTCOMES, 2021, 8 (04) : 537 - 545
  • [42] Retrospective Analysis of Real-World Treatment Patterns and Survival Outcomes for Non-small Cell Lung Cancer Patients in Thailand
    Supaattagorn, S.
    Maneenil, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S603 - S604
  • [43] European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review
    Riyaz Shah
    Nicolas Girard
    Saurabh P. Nagar
    Frank Griesinger
    Julia Roeper
    Keith L. Davis
    Parisa Karimi
    William Sawyer
    Ning Yu
    Aliki Taylor
    Josephine Feliciano
    Drugs - Real World Outcomes, 2021, 8 : 537 - 545
  • [44] A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC)
    Nieva, J.
    Karia, P. S.
    Okhuoya, P.
    Berktas, M.
    Salomonsen, R. J-B.
    Servidio, L.
    Chapaneri, J.
    De Silva, K.
    Martin, E.
    Griesinger, F.
    ANNALS OF ONCOLOGY, 2023, 34
  • [45] Clinical Activity of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib
    Gadgeel, Shirish
    Chen, Wei
    Piotrowska, Zofia
    Goldman, Jonathan W.
    Wakelee, Heather
    Camidge, D. Ross
    Varga, Andrea
    Yu, Helena
    Papadimitrakopoulou, Vassiliki
    Nea, Joel
    Soria, Jean-Charles
    Wozniak, Antoinette
    Riely, Gregory
    Narayanan, Vignesh
    Mendenhal, Melody
    Sequist, Lecia
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1263 - S1263
  • [46] Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)
    Sakata, Yoshihiko
    Saito, Go
    Sakata, Shinya
    Oya, Yuko
    Tamiya, Motohiro
    Suzuki, Hidekazu
    Shibaki, Ryota
    Okada, Asuka
    Yokoyama, Toshihide
    Matsumoto, Hirotaka
    Otsuki, Taiichiro
    Sato, Yuki
    Junji, Uchida
    Tsukita, Yoko
    Inaba, Megumi
    Ikeda, Hideki
    Arai, Daisuke
    Maruyama, Hirotaka
    Hara, Satoshi
    Tsumura, Shinsuke
    Morinaga, Jun
    Sakagami, Takuro
    LUNG CANCER, 2023, 186
  • [47] Real-world disease characteristics and treatment patterns in patients with advanced non-small cell lung cancer and EGFR in Brazil and Taiwan
    Bailey, H.
    Burlison, H.
    Chandrasekar, S.
    Wong, C. H.
    Forshaw, C.
    Duncan, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S58 - S58
  • [48] A real-world survival of subsequent therapy in ALK positive non-small cell lung cancer (NSCLC) patients with crizotinib resistance.
    Yang, Lu
    Ma, Di
    Xu, Fei
    Xu, Haiyan
    Li Junling
    Xing, Puyuan
    Hao, Xuezhi
    Wang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    Schuler, A.
    Huser, J.
    Schaer, S.
    Schmid, S.
    Scherz, A.
    Gautschi, O.
    Mauti, L. A.
    Von Briel, T.
    Waibel, C.
    De Nicola, L. Wannesson
    Pankovics, J.
    Mark, M. T.
    Rothschild, S. I.
    Addeo, A.
    Janthur, W-D.
    Siano, M.
    Britschgi, C.
    Frueh, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1585
  • [50] Real-World Outcomes Among Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
    Waterhouse, D.
    Iadeluca, L.
    Sura, S.
    Zhou, J.
    Wilner, K.
    Emir, B.
    Espirito, J.
    Bartolome, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S317 - S317
12345